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Abstract
Surfactant protein-A (SP-A) has well-established functions in reducing bacterial and viral infections but its role in chronic
lung diseases such as asthma is unclear. Mycoplasma pneumoniae (Mp) frequently colonizes the airways of chronic
asthmatics and is thought to contribute to exacerbations of asthma. Our lab has previously reported that during Mp
infection of non-allergic airways, SP-A aides in maintaining airway homeostasis by inhibiting an overzealous TNF-alpha
mediated response and, in allergic mice, SP-A regulates eosinophilic infiltration and inflammation of the airway. In the
current study, we used an in vivo model with wild type (WT) and SP-A
2/2 allergic mice challenged with the model antigen
ovalbumin (Ova) that were concurrently infected with Mp (Ova+Mp) to test the hypothesis that SP-A ameliorates Mp-
induced stimulation of eosinophils. Thus, SP-A could protect allergic airways from injury due to release of eosinophil
inflammatory products. SP-A deficient mice exhibit significant increases in inflammatory cells, mucus production and lung
damage during concurrent allergic airway disease and infection (Ova+Mp) as compared to the WT mice of the same
treatment group. In contrast, SP-A deficient mice have significantly decreased Mp burden compared to WT mice. The
eosinophil specific factor, eosinophil peroxidase (EPO), which has been implicated in pathogen killing and also in epithelial
dysfunction due to oxidative damage of resident lung proteins, is enhanced in samples from allergic/infected SP-A
2/2 mice
as compared to WT mice. In vitro experiments using purified eosinophils and human SP-A suggest that SP-A limits the
release of EPO from Mp-stimulated eosinophils thereby reducing their killing capacity. These findings are the first to
demonstrate that although SP-A interferes with eosinophil-mediated biologic clearance of Mp by mediating the interaction
of Mp with eosinophils, SP-A simultaneously benefits the airway by limiting inflammation and damage.
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Introduction
Eosinophils, the highly granular proinflammatory leukocytes
important in the body’s host defense against parasites, such as
helminths, have also been implicated in the pathogenesis of many
inflammatory conditions ranging from skin and gastroenteric
diseases to allergy and bronchial asthma (reviewed in [1,2]).
Asthma affects approximately 20 million people in the US and is
now one of the most common chronic diseases of childhood,
involving roughly 10% of children [3,4]. While onset of asthma
symptoms can be triggered by a myriad of initiating stimuli such as
cold air, exercise, air pollutants and allergens, asthma exacerba-
tions are now being increasingly linked to pulmonary infection
with Mycoplasma pneumoniae (Mp) [5,6,7,8].
Mp, the causative agent of ‘‘walking pneumonia,’’ often
colonizes the airways of chronic asthmatics. In fact, recent studies
report that greater than 50% of chronic stable asthmatics have
evidence of airway infection with Mp [8] and that the majority of
children taken to the emergency room during their initial
asthmatic episode are colonized with Mp [9,10]. While eosinophils
have been implicated in asthma pathogenesis and eosinophil
granular proteins are often found in bronchoalveolar lavage and
serum in asthma patients, the contribution of eosinophils in Mp-
induced exacerbations of allergic airways has not been previously
described.
Surfactant protein-A (SP-A), a secretory product of airway and
alveolar epithelial cells, is known to have important roles in host
defense against microbes, although relatively little is known about
the role of SP-A in asthma. Studies show that SP-A levels are
reduced in asthmatics who are segmentally challenged with
allergen [11] and previous studies from our lab show that SP-A
deficient mice have enhanced airway hyperresponsiveness (AHR)
and inflammation when infected with Mp alone [12]. Additionally,
SP-A binds to Mp through phospholipids and through a specific
binding protein [13,14], further suggesting the importance of SP-A
in mediating the immune response to this pathogen.
The goal of the current study is to evaluate the role of SP-A in
mediating eosinophil responses to Mp infection in an allergic lung.
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airways followed by Mp infection (Ova+Mp), we find that
eosinophils are potent killers of Mp and that SP-A benefits airway
homeostasis by limiting eosinophil activation that may lead to lung
inflammation and damage. However, SP-A also inhibits eosino-
phil-mediated clearance of Mp by reducing eosinophil peroxidase
(EPO) release. Thus, we demonstrate for the first time that SP-A
acts as a double-edged sword in the host response to Mp infection
in the setting of allergic airway disease.
Results
Mp burden in Mp-infected allergic mice
Previously, others have shown that by binding SP-A, Mp growth
is restricted in vitro [13,14], and our lab has shown that SP-A is
vital in curtailing an overzealous TNF-mediated response to Mp
by attenuating airway hyperresponsiveness and mucus production
compared to WT infected mice [12]. To determine the role of SP-
A in mediating the immune response to Mp in an allergic airway,
we used the Ova-sensitization and challenge protocol, followed by
intranasal infection with Mp (fig. 1A), similar to methods
previously described [15]. Bronchoalveolar lavage (BAL) was
plated to obtain CFUs and RT-PCR was performed from whole
lung cDNA for Mp specific P1-adhesin gene. Surprisingly, SP-A
2/
2 mice had a significantly lower Mp burden measured in both
BAL (fig. 1B) and lung tissue samples three days post infection
(fig. 1C). This is in contrast to our previously published findings in
non-allergic airways, such as those infected and harvested prior to
the ova challenge on day 20 (no eosinophils are present in the BAL
or tissue) where Mp burden is similar in BAL fluid in WT and SP-
A
2/2 mice (,1610
4 Mp CFU/ml), and significantly greater in
the airway tissue (,20 fold greater) when SP-A is absent [12]. Our
findings in allergic airways show that SP-A
2/2 mice have
decreased Mp burden as compared to WT mice in the BAL and
lung tissue, as well as higher numbers of eosinophils three days
post infection (fig. 2F). Mp infection was resolving by day seven in
allergic WT and SP-A
2/2 mice as Mp burden was similarly
decreased in BAL and lung tissue compared to three days post
infection in both groups of mice (data not shown). Taken together,
these findings suggest that eosinophils, which are only found in
allergic airways, are the key cell type leading to the decreased Mp
burden in SP-A
2/2 allergic mice and when more eosinophils are
present, such as in the SP-A
2/2 mice, less Mp remain. In non-
allergic airways, where no eosinophils are present, more Mp
burden persists in SP-A
2/2 mice as compared to WT mice, likely
due to the absence of SP-A to bind Mp and help resolve infection
through mucociliary clearance mechanisms. Taken together, these
findings also suggest that SP-A mediates Mp clearance by different
mechanisms in non-allergic versus allergic lungs.
Recruitment and activation of eosinophils
In order to determine which cell types could be responsible for
the increased Mp killing/clearance in the allergic SP-A deficient
mice, we compared cell populations from WT and SP-A null mice
that were Ova sensitized/challenged and infected with Mp and to
controls that were either exposed to the Ova challenge only (no
Mp) or given saline. There were no significant differences between
WT and SP-A
2/2 mice in any of the cell populations examined in
either saline treated or saline aerosolized mice (data not shown).
Using flow cytometry of cells stained with antibodies against
Figure 1. Mp burden is decreased in Mp-infected SP-A
2/2 allergic mice. A) WT and SP-A
2/2 mice were injected ip with Ova/Alum mixture
on days 1 and 14, subject to Ova aerosolization on days 21–23 and instilled with either Mp or saline on day 25. Mp burden was determined in B) BAL
by plating dilutions on PPLO agar plates and counting via 106 magnification or in C) lung tissue by RT-PCR for Mp P1-adhesin relative to
housekeeper. n=at least 15 mice/group, 3 experiments combined, **p,.01.
doi:10.1371/journal.pone.0032436.g001
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more macrophages (Macs), CD11b+ exudative macrophages (Ex-
Macs), inflammatory monocytes (IMs), dendritic cells (DCs),
neutrophils (PMNs) and eosinophils (Eos) present in BAL of
allergic/infected SP-A null mice as compared to WT mice
(fig. 2A–E), further suggesting an important regulatory role of
SP-A in this allergic/infectious model.
Interestingly, we found no eosinophils in our previous studies
examining Mp infection in a non-allergic airway lacking SP-A,
although we did see increases in the other cell populations.
Samples from the Ova+Mp experimental model were collected on
day 28 (5 days after the last Ova aerosol in Ova only and in
Ova+Mp treated mice), the time at which airway physiology
measurements were also conducted. Previous publications from
our lab have established that on day 24 of the Ova only model, SP-
A
2/2 mice have even more pronounced eosinophilia than their
WT controls [16]. We therefore verified in control groups of mice
that the number of eosinophils present 48 hrs after the last Ova
aerosol (on day 25 when mice are infected with Mp) remained
significantly elevated in SP-A
2/2 mice as compared to WT mice,
as has been previously published. The finding that eosinophils are
decreased in the Ova only groups by day 28 of our model, as
compared to the previously published findings on day 24 [16],
suggests that eosinophilia is resolving in the Ova only control
groups of WT and SP-A
2/2 mice.
Lungs were harvested from three groups of WT and SP-A null
mice: 1) saline treated control mice, 2) Ova sensitized/challenged
mice, 3) and Ova sensitized/challenged and Mp infected mice. To
determine if SP-A regulates eosinophil activation to Mp infection
in the allergic mice, markers of eosinophils, such as IL-5 and
eosinophil associated ribonuclease (EAR), were analyzed by RT-
PCR. In Ova allergic WT and SP-A
2/2 mice, the levels of IL-5
and EAR RNA were dramatically but comparably increased over
levels detected in samples taken from saline treated mice,
suggesting similar numbers eosinophils were present in the lungs
of WT and SP-A
2/2 mice 5 days post Ova challenge.
Interestingly, EAR expression, a marker typically associated with
eosinophil activation, is significantly increased in the WT
Ova+Mp compared to the WT Ova alone. This increase in
EAR expression suggests that while the total eosinophil number is
similar between the WT groups, the activation status of the
eosinophils, as determined at the transcriptional level, in the WT
Ova+Mp group is greater than in the WT Ova only. Additionally,
when Ova allergic SP-A
2/2 mice are infected with Mp, the levels
of IL-5 and EAR RNA significantly increased over levels detected
in the Ova allergic WT infected mice. This suggests that not only
are more eosinophils present in the SP-A
2/2 Ova+Mp mice, but
also that SP-A may reduce the activation of eosinophils at the
transcriptional level (fig. 3A,B).
Lung sections were analyzed from Ova sensitized/challenged
Mp infected SP-A
2/2 and WT mice by histochemical staining for
cyanide resistant EPO activity. While the majority of EPO activity
staining is observed in the lung parenchyma in the allergic infected
WT mice (fig. 3C, upper panel), more staining was evident
around the large airways of allergic infected SP-A
2/2 mice, in
close proximity to where we and others have shown Mp to
colonize [12] (fig. 3C, lower panel). Additionally, EPO activity
was measured in both BAL and lung tissue from Mp-infected
allergic mice. The total EPO activity measured in the infected
allergic mice lacking SP-A was significantly greater than that in the
control WT mice given the same treatment (fig. 3D).
Binding of SP-A to eosinophils
In order to assess the possibility that SP-A acts directly on
eosinophils to modulate their responses, we sought to determine if
SP-A binds to eosinophils. Eosinophils were purified from the
blood of IL-5 transgenic mice and their purity determined to be
greater than 95% by cytospin analysis of H&E staining and/or by
positive cell surface labeling with the CCR3 antibody by flow
cytometry. SP-A bound to eosinophils in a dose dependent
manner (fig. 4A); only minimal binding of a control protein, non-
immune IgG control was detected (fig. 4B). To test the Ca
2+
dependency of SP-A binding to eosinophils, assays were performed
in the presence or absence of EDTA. Binding of SP-A to
eosinophils was optimal in Ca
2+-rich buffer (fig. 4A) and was
significantly repressed with the addition of EDTA (fig. 4C).
Images visualized with a confocal microscope also demonstrate the
Figure 2. Recruitment of inflammatory cells is enhanced in Mp-
infected SP-A
2/2 allergic mice. A–F) Cells in the BAL were
examined by cell surface labeling, as described in the methods section,
and flow cytometry 3 days after Mp infection (day 28 of the model).
Macs (macrophages), Ex-Macs (exudative macrophages), IMs (inflam-
matory monocytes), DCs (dendritic cells), PMNs (neutrophils), Eos
(eosinophils). n=at least 12 mice/group, 3 experiments combined,
*p,.05, **p,.01.
doi:10.1371/journal.pone.0032436.g002
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control (inset panels). SP-D has been reported to bind
eosinophils via the FC receptor [17]. To determine if SP-A also
binds eosinophils through the FC receptor, binding of SP-A was
determined after eosinophils had been pre-incubated with an FC-
antibody. Binding of SP-A to eosinophils was dramatically reduced
when cells were incubated with the FC antibody prior to the
addition of SP-A as shown by flow cytometry (fig. 4D).
Involvement of eosinophils in Mp killing
In contrast to our previously published data showing that SP-
A
2/2 mice had significantly more Mp colonizing the large airway
compared to WT mice, the SP-A
2/2 mice challenged with Ova
and infected with Mp have significantly decreased Mp burden
compared to WT Ova+Mp challenged mice. Interestingly,
eosinophils are only present in the infected allergic mice (not
present in the Mp infected only) and are significantly higher in the
BAL of SP-A
2/2 mice compared to WT mice at the time of Mp
instillation and at the time of harvest 3 days post infection. These
findings suggest that eosinophils may be important mediators of
Mp clearance in allergic airways.
In order to determine if eosinophils kill Mp, eosinophils were
purified from the blood of IL-5 transgenic mice and co-incubated
with Mp for 1 hour. In the first 15 minutes, ,75% of the Mp was
killed by eosinophil-mediated mechanisms, and by 60 minutes less
than 10% of Mp remained viable (fig. 5A). Additionally, pre-
incubation of eosinophils with a physiological concentration of SP-
A prior to Mp addition, interfered with their killing mechanisms as
compared to control eosinophils incubated with control buffer
(fig. 5B). These experiments support the in vivo data where we
observed less Mp burden when more eosinophils are present (as in
the SP-A
2/2 mice). Since SP-A is known to bind Mp, we did the
reverse experiment in which SP-A was pre-incubated with Mp
prior to addition to eosinophils in culture. SP-A bound to Mp also
Figure 3. Eosinophil mediators are increased in the absence of SP-A. On day 28 of the Ova+Mp model, lungs were harvested and A) IL-5 and
B) EAR were assessed by RT-PCR. C) Histochemical staining for EPO positive eosinophils was done 1 day after Mp infection and is representative of 3
experiments, n=5/group. D) Total EPO activity in BAL and lung tissue from Ova+Mp mice was determined via colorimetric assay and absorbance read
at 492 nm. n=combined 3 experiments, *p,.05, **p,.01.
doi:10.1371/journal.pone.0032436.g003
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compared to the Mp that was pre-incubated with the buffer
control (fig. 5C). Since both sets of experiments, eosinophils pre-
incubated with SP-A and Mp pre-incubated with SP-A, were
centrifuged after the pre-incubation to remove any unbound SP-A,
our findings suggest the binding of SP-A to either eosinophils or
Mp is sufficient to interfere with eosinophil-mediated Mp killing.
Pre-incubation with SP-D did not affect the ability of eosinophils
to kill Mp (fig. 5D).
SP-A inhibits EPO release from Mp-stimulated eosinophils
EPO has long been known to be an important agent against
multicellular parasites and some bacteria, including M. tuberculosis
[18]. Significantly more EPO activity was found in samples
harvested from infected allergic mice lacking SP-A as compared to
WT mice with the same treatment. Since more eosinophils in the
SP-A
2/2 infected allergic mice could account for the increased
EPO, we did in vitro studies to determine if exogenously added
human SP-A inhibits EPO release from activated eosinophils.
While stimulation of eosinophils with Mp resulted in significant
EPO activity in the supernatant, SP-A pre-incubation at
physiologic concentrations with the eosinophils reduced the
amount of EPO released dose-dependently (fig. 5E). The viability
of the cells was assessed and there were no significant differences in
any of the treatment groups (all groups had less than 5%
cytotoxicity) indicating that cell death was not a cause of increased
EPO release (not shown). As a control, another surfactant known
to bind eosinophils, SP-D [17], used at physiologic concentrations,
was unable to inhibit EPO release from Mp-stimulated eosinophils
(fig. 5F) suggesting that the inhibition of Mp-stimulated EPO
release is not a shared function of the lung collections. As
described for eosinophil mediated Mp killing above, binding of SP-
A to either Mp or to the eosinophils prior to their addition to the
assay resulted in decreased EPO release into the supernatant
(fig. 5G), supporting the importance of direct interaction of Mp
with the eosinophil to initiate EPO release.
Levels of surfactant proteins during allergy and infection
Surfactant levels are known to change in certain inflammatory
conditions. Since alterations in either SP-A or SP-D levels during
allergic and infectious conditions could potentially influence the
killing capacity of eosinophils, we sought to determine levels of
each surfactant in the BAL of allergic and allergic/infected mice
using densitometry measurements of Western blots. SP-A levels
were similar in WT mice among untreated controls, Ova treated
(day 28 of our model: 5 days after the last aerosol) and in Ova+Mp
treated (day 28 of our model: 5 days after the last aerosol/3 days
after Mp infection) (fig. 6A). SP-D levels were decreased similarly
(although they did not achieve statistical significance) in both WT
and SP-A
2/2 mice in Ova treated mice as compared to untreated
Figure 4. SP-A binds to eosinophils in a Calcium-dependent
manner. Eosinophils were incubated with A) fluorescent labeled SP-A-
DY649 (shaded=unstained cells, turquoise=0.1 mg/ml, pink=1 mg/ml,
purple=10 mg/ml) in calcium-rich buffer or B) fluorescent labeled IgG
in calcium-rich buffer (at the same concentrations used above) or C)
fluorescent labeled SP-A in calcium depleted buffer and binding was
assessed by flow cytometry. SP-A binding (10 mg/ml) to labeled
eosinophils was also observed with confocal microscopy as shown in
the insets. DAPI (blue stain) and SP-A-DY649 (pink stain) stained slides
were examined at 406via confocal microscopy. D) SP-A binding of the
percentage of highly positive cells (gated at 5610
3) was assayed by
flow cytometry (geomean of DY649) after cells were pre-incubated with
FC antibody (pink line) versus SP-A alone (purple line).
doi:10.1371/journal.pone.0032436.g004
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SP-D were similar to untreated controls (fig. 6B). These findings
show that five days after the last Ova aerosol in non-infected and
in Mp-infected mice, SP-A levels remain similar to levels in
untreated mice. Additionally, SP-D levels are not decreased during
Ova+Mp conditions as compared to untreated controls and the
amount of SP-D is not significantly different between WT and SP-
A
2/2 mice in any of the treatment groups examined, suggesting a
limited contribution of SP-D to the observed killing phenotype.
Contribution of EPO to Mp killing
Our in vivo data suggests that the presence of SP-A appears to
interfere with eosinophil mediated killing of Mp and our in vitro
data suggests that one mechanism through which SP-A exerts this
affect is by binding eosinophils and limiting EPO release when
they encounter Mp. Therefore, to determine if EPO can directly
kill Mp, purified EPO was added to Mp cultures for 1 hour and
Mp viability was assessed. When used at a similar concentration
(0.5 mM) reported to kill M. tuberculosis [18], EPO killing of Mp
appears to be rapid, with 75% of the pathogen eliminated in the
first 30 minutes of incubation (fig. 7A).
Because we observed EPO kills Mp in vitro and because SP-A
2/
2 mice have more EPO present in BAL and lung samples and less
Mp burden, we tested whether an inhibitor of EPO activity would
result in decreased clearance of Mp in the allergic SP-A
2/2 mice.
Mice were sensitized and challenged with Ova as described above.
Immediately prior to Mp infection, mice were given an injection of
the peroxidase inhibitor, resorcinol, as previously described [19].
Resorcinol treatment did not affect the percentage of eosinophils
recruited in the BALs (data not shown). As expected, Mp infected
allergic SP-A
2/2 mice given vehicle (PBS) had significantly less
Mp burden than Mp infected allergic WT mice given vehicle
(fig. 7B). However, allergic SP-A
2/2 mice given resorcinol were
unable to clear the Mp as well as allergic SP-A
2/2 mice given
vehicle (fig. 7B) suggesting that the increased clearance observed
in the SP-A
2/2 mice could be attributed to increased EPO
activity.
Mucus production and lung damage in Mp-infected
allergic airways
A part of the immune response to Mp infection in an allergic
airway is dramatically heightened mucus production by goblet
cells. While PAS stained cells were increased in Ova treated and in
Mp-infected Ova treated airways of both WT and SP-A
2/2 mice
as compared to saline controls, SP-A
2/2 mice had significantly
more PAS positive cells evident even in large airways and distal
bronchioles compared to WT mice in each of the treatment groups
(fig. 8A,B). Resorcinol treatment did not affect the percentage of
PAS positive cells in the large airways (data not shown). In
conjunction with our previous data presented in this manuscript,
this indicates there is no correlation between Mp burden and
mucus production in the large airway in our mouse model.
Albumin levels in the BAL were measured as another gauge of
lung damage and permeability. Albumin is one of the most
abundant proteins in the bloodstream and as lungs are damaged,
as in the case of severe inflammation, weakened pulmonary blood
vessels allow leakage from the bloodstream into the lung tissue and
airspaces. Typically, a heightened amount of albumin in BAL is
Figure 5. Eosinophil-mediated Mp killing is attenuated by exogenous SP-A. A) Purified eosinophils were added to Mp (10:1) for 1 hr and
aliquots were diluted on PPLO agar plates for CFU counts. B) Mp and C) Eosinophils were pre-incubated with SP-A (10 mg/ml) for 30 minutes to allow
for binding and centrifuged prior to their addition to the killing assay. D–F) SP-D (0.5–5 mg/ml) or SP-A (5–10 mg/ml) was pre-incubated with
eosinophils prior to the addition of Mp MOI 10:1. EPO was measured in the supernatant after 1 hr of stimulation. G) Mp or Eosinophils were pre-
incubated with SP-A (10 mg/ml) for 30 minutes to allow for binding and centrifuged prior to their addition to the EPO stimulation assay *p,.05,
**p,.01, n=3 experiments.
doi:10.1371/journal.pone.0032436.g005
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or vascular permeability. Ova treated WT and SP-A
2/2 mice had
significantly increased albumin in BAL samples as compared to
saline treated mice. Additionally, Ova treated mice lacking SP-A,
had significantly more albumin in BAL as compared to WT Ova
treated mice (fig. 8D). Not surprisingly, Mp-infected allergic mice
either sufficient or deficient in SP-A had increased inflammation
and albumin in their BAL compared to saline treated mice and to
Ova treated mice (fig. 8C,D). However, mice lacking SP-A had
more pronounced red blood cells infiltrating the lung parenchyma
(fig. 8C) and significantly greater levels of BAL albumin than did
WT mice (fig. 8D).
Discussion
Mp is currently believed to be one of the most common
pathogens linked to asthma exacerbations (reviewed in [20]).
Studies in mice have demonstrated that infection of an Ova
allergic airway with Mp augments airway hyperreactivity and
inflammation compared to that observed in an Ova allergic airway
alone [15], providing additional evidence for the link between Mp
infection and chronic asthma as observed in humans. The present
work shows that SP-A plays a dual role in allergic airways with Mp
superinfection. SP-A protects the airway by limiting cellular
inflammation, eosinophil activation and release of eosinophil
products such as EPO, all of which may lead to airway damage.
However, perhaps as a consequence of this anti-inflammatory role,
SP-A simultaneously appears to interfere with eosinophil-mediated
biologic clearance of Mp by curtailing EPO-driven killing
mechanisms.
The release of cationic proteins from activated airway
eosinophils has been implicated as a possible mechanism
contributing to exacerbations in chronic asthmatics. Granular
products, such as MBP and EPO, are thought to induce epithelial
damage and airway constriction, and EPO itself has been linked to
airway remodeling [21]. However, it is unknown if Mp
colonization of eosinophil-laden airways, as is common in many
asthmatics, results in eosinophil activation and subsequent
degranulation. Prior publications have reported that eosinophil
Figure 6. Alteration of surfactant levels during inflammation
and infection. A) SP-A or B) SP-D levels were determined by
densitometry of Western blots of BAL samples of untreated, Ova only
(day 28 of our model) or Ova+Mp (day 28 of our model). n=2
experiments with 3–4 mice/group each.
doi:10.1371/journal.pone.0032436.g006
Figure 7. EPO is vital for Mp killing mechanisms in vitro and in
vivo.A ) Purified human EPO (0.5 mM) was added to Mp (5610
6) and
viability was assessed over the course of 1 hr. **p,.01,*p,.05. n=3
experiments. B) Mice were treated with Ova and Mp (O+Mp) as
previously described but 2 hrs prior to Mp infection, some mice were
given either vehicle (V) or resorcinol (R). Mice were given boosters after
24 hrs and samples harvested at 72 hrs for Mp burden. *p,.05. n=2
experiments (8–10 mice/group).
doi:10.1371/journal.pone.0032436.g007
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[22], which our data support. However, when Mp infects an Ova
challenged airway, we find evidence of eosinophil activation, as
shown by increased EAR transcription, and increased EPO in
BAL and tissue samples, suggesting that eosinophil degranulation
has also occurred.
Surfactant proteins have long been recognized as modulators of
the innate immune system in part by directly binding to a variety
of inflammatory cell types [23,24,25,26]. Discrepancies exist in the
field regarding the levels of surfactant proteins after allergen
provocation. Surfactant proteins measured in BAL from humans
with asthma have been reported to both increase and decrease
(reviewed in [27,28]). Recent studies, however, have shown that in
segmentally challenged asthmatics, SP-A levels are decreased
while SP-D levels were increased [11]. Previous work by Schmiedl
et al showed increases in both SP-A and SP-D acutely in an Ova
model [29]. However, in our model of Ova challenge when we
examine surfactant levels during the resolution phase (5 days post
challenge), we find that SP-A levels are similar to untreated
controls while SP-D levels are slightly decreased.
Current studies in the field suggest that SP-A may be
dysfunctional in several lung diseases such as Respiratory Distress
Syndrome, Idiopathic Pulmonary Fibrosis, and asthma possibly
due to genetic variants [30,31,32,33,34,35]. This decrease in
functional SP-A in asthmatics may be associated with increases in
Mp-induced exacerbations seen in allergic airways as compared to
Mp infections in non-allergic airways. Additionally, Mp clearance
in non-allergic airways is typically driven by macrophages and
mucocilliary actions while eosinophils are rarely present [36]. In
contrast, eosinophils are commonly present in the airways of
Figure 8. SP-A is protective against Mp-induced allergic pathologies. A) PAS stained lung sections examined at 106magnification were B)
blindly scored for mucus production with 0 representing no mucus present and 5 being mucus present in greater than 75% of airways and
bronchioles. C) H&E stained lung sections shows inflammation and RBCs in alveolar spaces and lymphatics of Ova+Mp treated mice. D) Albumin
measured in the BAL as a measure of lung damage and vascular permeability. n=representative of 3 experiments, *p,.05.
doi:10.1371/journal.pone.0032436.g008
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findings in mice, if SP-A is absent or dysfunctional in the asthmatic
airway, colonization with Mp would most likely result in
eosinophil activation and degranulation. We are the first to report
that SP-A binds eosinophils directly and inhibits their release of
EPO. While the limited release of EPO may interfere with the
body’s natural response to clear Mp, we speculate that decreased
release of other harmful cationic products will aid in protecting the
airway from damage due to excessive inflammation.
Previous work by our lab showed that SP-A regulated the
interaction between Mp and DCs via TLR-2, and SP-A pre-
incubated and bound to Mp was critical in limiting Mp from
interacting with TLR-2 on dendritic cells [37]. Interestingly, pre-
incubating dendritic cells with SP-A was not as effective at
reducing Mp stimulation. In the case of eosinophils, however, SP-
A binding to either the eosinophil or to the Mp seems to be
important in regulating the EPO-driven killing activities of the
eosinophils. This suggests the engagement of Mp with the
eosinophil is critical in EPO release and subsequent killing of
Mp by the eosinophil. When this engagement is altered with either
SP-A binding to the eosinophil or with SP-A binding to the Mp,
EPO release and killing of Mp by the eosinophil is limited.
Recent findings show that intestinal eosinophils express high
levels of SIRP-a, an inhibitory receptor signal regulatory protein,
and that cross-linking of SIRP-a on the surface of eosinophils
significantly reduced the amount of EPO released during
stimulation with a calcium ionophore [38]. While our findings
demonstrate that SP-A binds eosinophils through the FC receptor,
interestingly, SP-A has also been shown to bind directly to SIRP-a
on the surface of other cells, such as macrophages [39].
Additionally, since Mp stimulates cells almost exclusively through
TLR-2 [37,40], SP-A may bind Mp and limit the ability of the Mp
to signal via TLR-2, which results in decrease EPO release from
the eosinophils. Future studies should investigate whether lung
eosinophils express SIRP-a and whether the mechanism by which
SP-A limits EPO release from Mp-stimulated eosinophils involves
any of these receptors in which SP-A is known to interact.
While multiple cell types were increased in the SP-A
2/2 Mp
infected allergic mice compared to WT of the same treatment, we
had strong reason to believe that eosinophils were responsible for
the decreased Mp burden. First, in non-allergic SP-A
2/2 mice
infected with Mp the burden and colonization in the large airway
was significantly greater than in WT mice [12]. In the Mp-infected
(non-allergic) mice, many of the cell types in the SP-A
2/2 mice
were also significantly increased as compared to WT mice of the
same treatment (macrophages, exudative macrophages, and
dendritic cells are all increased in the SP-A
2/2 mice; neutrophils
and inflammatory monocytes are similar between WT and SP-
A
2/2 mice; no eosinophils are present). Although greater numbers
of other inflammatory cells persist when SP-A is absent that could
kill Mp, Mp burden in the lung tissue is significantly greater in SP-
A
2/2 mice [12]. This suggests that the same populations of cells
present in the non-allergic lungs (macrophages, exudative
macrophages, dendritic cells, neutrophils and inflammatory
monocytes) are likely not contributing to the increased killing
mechanisms we observe in the allergic lung. Thus, the only
population different that we observe between the non-allergic and
allergic lung cell populations that can kill Mp, are the eosinophils.
Eosinophils numbers were increased only in the Mp-infected
allergic model but not in the Mp-infected non-allergic model.
While eosinophils were significantly increased at the time of
harvest, 3 days post infection, sampling was done immediately
prior to Mp infection in a group of mice and eosinophils present
from the Ova challenge alone were even higher and significantly
elevated in the SP-A
2/2 mice as compared to WT controls. This is
in agreement with previously published reports from our lab in the
Ova sensitization and challenge model in SP-A
2/2 versus WT
mice [16].
In conclusion, our work demonstrates that Mp causes eosinophil
activation and EPO release and that SP-A plays dual roles as both
protective, by limiting these harmful responses, and intrusive, by
inhibiting eosinophil mediated Mp killing. Mp infected mice
lacking SP-A have increased inflammation, vascular permeability,
and mucus production as compared to Mp infected mice sufficient
in SP-A. While SP-A interferes with the ability of the eosinophil to
naturally kill Mp by inhibiting the engagement of the eosinophil
with Mp and thereby reducing EPO release, SP-A simultaneously
protects the lung by limiting Mp-induced eosinophil activation and
release of other potentially harmful products into the airway.
Additionally, we are the first to show that eosinophils kill Mp
through EPO-driven mechanisms and that when EPO is
neutralized in vivo, Mp clearance is impaired. Thus, SP-A is
pivotal in maintaining homeostasis in the pulmonary environment
by preserving a fine balance between mounting host defense
mechanisms while limiting an overzealous response that could
ultimately prove damaging to the host.
Methods
Ethics Statement
All mouse studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institute of Animal Care and Use
Committee (IACUC) at Duke University (protocol number A284-
09-09, approved on 9/23/10). All surgery was performed under
Ketamine (100 mg/kg)/Xylazine (5 mg/kg) anesthesia, and all
efforts were made to minimize suffering.
M. pneumoniae culture
Mp from ATCC (cat. #: 15531) was grown in SP4 broth
(Remel) at 35uC (without CO2) and passaged until adherent. Mp
concentration was determined by plating serial dilutions of Mp on
PPLO plates (Remel). CFUs were counted under 106 magnifi-
cation on plates after incubation for 7 to 14 days. For in vivo
infection, adherent Mp was washed by centrifuging at 6000 rpm
for 5 minutes and resuspended in sterile saline for infection. To
determine Mp counts from the BALs, 10 ml were plated on PPLO
plates and counts were recorded as described above after 14 days
of incubation.
RT-PCR
Lung tissue was collected and RNA extracted by phenol-
chloroform methods. cDNA was prepared according to standard
protocols and the amount of Mp was detected by RT-PCR by
using primers specific for the Mycoplasma pneumonia specific P1-
adhesion gene (forward 59 CGC CGC AAA GAT GAA TGA C
39, reverse 59 TGT CCT TCC CCA TCT AAC AGT TC 39).
Primers for IL-5 (forward 59 AGC ACA GTG GTG AAA GAG
ACC TT 39, reverse 59 TCC AAT GCA TAG CTG GTG ATT
T3 9) and EAR (forward 59 CGA CTT TGT CTC CTG CTG 39,
reverse 59 TGT CCC ATC CAA GTG AAC 39) were used.
Relative amounts of Mp P1-ahdesin, IL-5 or EAR present in each
infected lung were measured based on values obtained from a
standard curve for Mp P1-adhesin and were normalized to the
mammalian housekeeping gene cyclophilin or to ß-actin that was
present in the lung tissue.
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Wild type and SP-A
2/2 mice were maintained on a C57Bl/6
(Charles River) background and were 8–12 weeks of age at the
time of harvest. SP-A
2/2 mice were generated by homologous
recombination as described previously [41]. IL-5 transgenic mice
(NJ1638) were a generous gift from Dr. J.J. Lee, Mayo Clinic [42].
All mice used in experiments were on protocols approved by the
Institutional Animal Care and Use Committee at Duke University.
Ova+Mp infection model
WT and SP-A
2/2 mice were sensitized via intraperitoneal (i.p.)
injections of Ova (Sigma) emulsified in Aluminum Hydroxide gel
(Sigma) on days 1 and 14 and challenged with Ova aerosol on days
21–23 (1% aerosol nebulizer). Mice received either saline or Mp
instillation (1610
8 in 50 ml sterile saline under anesthesia via
ketamine/xylazine mix) on day 25, similar to published protocols
[15,43], to evaluate role of SP-A in Mp infection during allergic
airway disease. Some mice received i.p. injections of resorcinol
(1.25 mg/kg) or vehicle (PBS) 2 hours prior to Mp infection and
24 hours following infection [19].
Isolation of BALs and FACs Analysis
Mice were euthanized with a lethal dose of Nembutal. To
quantify cells in lung of uninfected SP-A
2/2 and WT mice,
animals were subjected to bronchoalveolar lavages with 6 mls of
37uC PBS (with 0.2 mM EDTA). BALs were resuspended in RBC
lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA)
and incubated on ice for 10 minutes. Cells were then resuspended
in buffer (HBSS 2Ca/2Mg, 10 mM EDTA, 5% FCS) and
counted using a hemacytometer. Flow cytometry was performed
using a BD LSRII at the Duke Human Vaccine Institute Flow
Cytometry Core Facility that is supported by the National
Institutes of Health award AI-51445. BAL cells were incubated
with fluorescent antibodies against specific cell surface markers:
FITC-MHC II, PE-Ly-6G, and APC-Cy7-GR-1 (BD Biosciences),
PE-Cy5-CD11c and APC-CD11b (eBioscience), PE-CCR3 (R &
D Systems). Macrophages were identified based on FSC vs SSC,
FITC autofluorescent, MHC II
lo-med, CD11c
+; Ex-Macs were
identified the same as macrophages but that are also CD11b+; IMs
were identified as Ly-6G
2, MHC II
2, CD11c
2, GR-1
+, CD11b
hi;
DCs were identified as MHC II
hi, CD11c
hi; PMNs were identified
as Ly-6G
+, GR-1
+; Eos were identified as CCR3
+, CD11b
+.
Determination of Albumin in Mouse BAL Samples
Mouse albumin concentrations were determined using an
immunoperoxidase assay from Immunology Consultants Labora-
tory, Inc. Briefly, BAL samples were diluted 1:100,000 and
incubated on a micro-titer plate that had rabbit anti-mouse
albumin polyclonal antibody bound to solid phase while detection
was based on streptavidin-peroxidase polymer. The plate was read
at 450 nm. The background value was subtracted from the test
values for each sample and the test sample values were
interpolated from the standard curve and multiplied for the
dilution factor.
Histological Analysis
On day three after Mp infection, WT and SP-A
2/2 mice were
euthanized by a lethal dose of Nembutal followed by exsanguina-
tion. The lungs were then perfused with 10 mls of warm PBS and
inflated by gravity flotation with 4% paraformaldehyde fixative.
Lungs were paraffin embedded, cutat 8 mm, and stained with either
H&E or PAS. Histochemical staining for eosinophils was done on
OCT frozen sections, cut at 10 mm as previously described [44].
Briefly, sections were incubated for 8 minutes at room temperature
in PBS supplemented with 3,3-diaminobenzidine tetrahydrochlor-
ide (60 mg/100 ml; Sigma), 30% H2O2 and NaCN (120 mg/
100 ml;Sigma). Slides were immersed in water,counterstained with
hematoxylin, mounted, and eosinophils identified based on their
darkbrownreaction product.Slidesthat wereassessed forPASstain
were done so in a blinded manner and rated on a scale of 0–5. A
score of 0 had no visible PAS stained cells, as seen in the saline
groups. Images of the lung were taken on a Nikon Eclipse 50i light
microscope at 610 (aperture 0.3) or 640 (aperture 0.75) at room
temperature by digital photography of bright-field images using a
Nikon Infinity 2 camera. Infinity Capture software was used for
image acquisition, and Adobe Photoshop was used for color-
contrast settings and figure presentation.
Eosinophil purification
Briefly, blood was collected via cardiac puncture from an IL-5
transgenic mouse into 0.5 ml EDTA tubes (Sarstedt). RBC were
lysed and cells were resuspended in 0.1% BSA in PBS. Biotin
labeled antibodies (1 ml per 10
7 cells) against B220 (CD45R) and
Thy 1.2 (CD90.2) were incubated with cells for 15 minutes on ice.
Cells were then resuspended in 0.1% BSA and Dynabeads were
added (1 mg/10
6 target cells up to 50 ml) and incubated for
30 minutes at 4uC with tube rotation every 5 minutes. Samples
were then placed into the magnetic apparatus with 4 mls additional
media for 5 minute increments to deplete the magnetically labeled
cells, leaving a greater than 95% pure population of eosinophils.
EPO activity assay
Purified eosinophils (,5610
5 per well) were stimulated with Mp
(5610
6 per well) for 1 hour in the presence or absence of different
concentrations of SP-A or SP-D. EPO activity was measured
based on methods that were adapted from previously published
protocols [22]. Briefly, 25 ml of either BAL, tissue homogenate, or
cell supernatant was added to a reaction buffer (50 mM Tris-HCl,
4m MH 2O2, 0.1% Triton X, 10 mM O-phenylenediamide) in
the presence or absence of the peroxidase specific inhibitor, 3-
amino-1,2,4-triazole (30 mM). The reaction was allowed to
proceed for 15–30 minutes at 37uC after which time stop solution
(2N H2SO4) was added and the plate read at 490 nm.
Eosinophil killing assay
Methods were adapted from Persson et al [45]. Briefly,
experiments were done in a 96-well plate setup and with
,5610
6 Mp were used per sample well. Some wells received
buffer controls while other received purified eosinophils at a
concentration of approximately 1 eosinophil per 10 Mp (,5610
5
cells: 5610
6 Mp). Some eosinophils were pre-incubated with SP-A
at a concentration of 40 mg/ml for 30 minutes and centrifuged at
1200 rpm for 5 minutes prior to their addition to Mp. Other
eosinophils (not incubated with SP-A) were also incubated for
30 minutes and centrifuged at 1200 rpm for 5 minutes in order to
maintain the same conditions throughout the treatment groups.
Viability of eosinophils was assessed at the end of each assay by
LDH (Abcam) testing in the supernatant. All samples had low and
equal amounts of LDH released during the hour-long incubation.
Some experiments were carried out with purified EPO (Lee
Biosolutions, Inc.) at a concentration of 0.5 mM, similar to
previously published methods [18].
SP-A preparation
SP-A was purified from the lung lavage fluid of patients with
alveolar proteinosis as described previously [46]. Briefly, the
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The resulting pellet was then sequentially solubilized in the
detergent octylglucoside and 5 mM Tris, pH 7.4. Extracted SP-A
was then passed over a polymyxin B-agarose column to reduce
endotoxin contamination. SP-A preparations had final endotoxin
concentrations of ,0.01 pg/mg SP-A as determined by the
Limulus amoebocyte lysate assay according to manufacturers’
instructions (QCL-1000, BioWhittaker (Lonza)). Some SP-A was
fluorescently labeled with DyLight Dy649 N-hydroxysuccinimide
ester (Pierce Thermo Fisher) in a Slidealyzer G2 10000 MWCO
cassette at pH 6.36 to maintain biological function. Excess reactive
dye was dialyzed out in PBS, pH 7.4 with three changes of 500-
fold excess buffer. The density of labeling averaged 2.6, using an
extinction coefficient of 72000 for SP-A.
SP-A binding to eosinophils
Once eosinophils were purified, approximately 5610
5 eosino-
phils were placed into tubes in either Ca
2+ rich (0.5% BSA,
0.9 mM CaCl2) or Ca
2+ depleted (0.5% BSA, 1 mM EDTA)
media. Different concentrations of either fluorescent SP-A or IgG
were added ranging from 0.1–10.0 mg/ml. Samples were incu-
bated on ice for a minimum of 30 minutes prior to centrifugation
at 1200 rpm for 5 minutes. Cells were then fixed in 2% formalin
and examined by flow cytometry. All binding studies were done on
ice to prevent eosinophil internalization of SP-A or IgG.
Statistical Analysis
All data measurements were analyzed with PRISM software
(GraphPad), first to determine if data were normally distributed,
followed by t-test to determine significance. Data sets with
significant variance between groups were analyzed by t-test using
Welch’s correction as assessed in PRISM. Statistical values of
*p,.05 and **,.01 unless otherwise noted.
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